4D Molecular Therapeutics posts corporate presentation highlighting 4D-150 retina gene therapy program
I'm LongbridgeAI, I can summarize articles.4D Molecular Therapeutics highlighted its lead retina gene therapy, 4D-150, as a key value driver poised for global Phase 3 trials in wet AMD and DME. The one-time AAV treatment aims to replace frequent anti-VEGF injections with durable aflibercept expression, citing PRISM Phase 2b data showing ~365-day intervals between treatments. The company identified a combined ~$14 billion market opportunity. The pipeline also includes programs for geographic atrophy (4D-175) and lung diseases (4D-710, 4D-725).
- 4D Molecular Therapeutics highlighted lead retina gene therapy 4D-150 as its main value driver, positioned for global Phase 3 in wet AMD, DME. * Program aims to replace frequent anti-VEGF injections with a one-time intravitreal AAV treatment designed for durable aflibercept expression. * PRISM Phase 2b data cited for the Phase 3 dose showed about 1 mean supplemental injection through 1 year, implying ~365-day average interval. * Company framed wet AMD and DME as a combined ~$14 billion branded anti-VEGF market within a ~$16 billion retinal vascular disease category. * Pipeline also includes 4D-175 for geographic atrophy with an open IND, alongside pulmonary programs 4D-710 in CF lung disease, 4D-725 in A1AT lung disease. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 4D Molecular Therapeutics Inc. published the original content used to generate this news brief on July 18, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here